Disease area
Hematologic malignancies
Multiple myeloma
B-cell malignancies
Myeloid malignancies
Classical hematology
Showing 4 recruiting clinical trials
Advanced or metastatic colorectal cancer
OrigAMI-1
Phase
b
NCT05379595
Compound
Amivantamab (EGFR × MET bispecific Ab) ± mFOLFOX6 or FOLFIRI
Unresectable or metastatic left-sided colorectal cancer
OrigAMI-2
Phase
NCT06662786
Compound
Amivantamab (EGFR × MET bispecific Ab) + mFOLFOX6 or FOLFIRI
Unresectable or metastatic colorectal cancer
OrigAMI-3
Phase
NCT06750094
Compound
Amivantamab (EGFR × MET bispecific Ab) + FOLFIRI
Metastatic colorectal cancer
89402638GIC1001
Phase
NCT06663319
Compound
JNJ-89402638 (GUCY2C × CD3)
The safety and efficacy of the investigational use of these products have not been determined.
There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency.
Ab, antibody; EGFR, epidermal growth factor receptor; FOLFIRI; 5-fluorouracil, leucovorin, and irinotecan; MET, mesenchymal epithelial transition factor; mFOLFOX6, 5-fluorouracil, leucovorin, and oxaliplatin.